Antonello Mai
Antonello Mai
Professore di Chimica Farmaceutica, Sapienza Università di Roma
Email verificata su
Citata da
Citata da
Histone deacetylation in epigenetics: an attractive target for anticancer therapy
A Mai, S Massa, D Rotili, I Cerbara, S Valente, R Pezzi, S Simeoni, ...
Medicinal research reviews 25 (3), 261-309, 2005
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration
D Palacios, C Mozzetta, S Consalvi, G Caretti, V Saccone, V Proserpio, ...
Cell stem cell 7 (4), 455-469, 2010
BLUEPRINT to decode the epigenetic signature written in blood
D Adams, L Altucci, SE Antonarakis, J Ballesteros, S Beck, A Bird, C Bock, ...
Nature biotechnology 30 (3), 224-226, 2012
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2
C Binda, S Valente, M Romanenghi, S Pilotto, R Cirilli, A Karytinos, ...
Journal of the American Chemical Society 132 (19), 6827-6833, 2010
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
E Lara, A Mai, V Calvanese, L Altucci, P Lopez-Nieva, ...
Oncogene 28 (6), 781-791, 2009
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead
A Mai, L Altucci
The international journal of biochemistry & cell biology 41 (1), 199-213, 2009
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides
A Mai, S Massa, R Pezzi, S Simeoni, D Rotili, A Nebbioso, ...
Journal of medicinal chemistry 48 (9), 3344-3353, 2005
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment
C Colussi, C Mozzetta, A Gurtner, B Illi, J Rosati, S Straino, G Ragone, ...
Proceedings of the National Academy of Sciences 105 (49), 19183-19187, 2008
Targeting histone demethylases: a new avenue for the fight against cancer
D Rotili, A Mai
Genes & cancer 2 (6), 663-679, 2011
The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery
HG Stunnenberg, S Abrignani, D Adams, M de Almeida, L Altucci, V Amin, ...
Cell 167 (5), 1145-1149, 2016
Oxidative stress and epigenetic regulation in ageing and age-related diseases
C Cencioni, F Spallotta, F Martelli, S Valente, A Mai, AM Zeiher, ...
International journal of molecular sciences 14 (9), 17643-17663, 2013
Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors
A Mai, S Massa, S Lavu, R Pezzi, S Simeoni, R Ragno, FR Mariotti, ...
Journal of medicinal chemistry 48 (24), 7789-7795, 2005
Dihydro (alkylthio)(naphthylmethyl) oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series
A Mai, M Artico, G Sbardella, S Quartarone, S Massa, AG Loi, A De Montis, ...
Journal of medicinal chemistry 40 (10), 1447-1454, 1997
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue
A Galmozzi, N Mitro, A Ferrari, E Gers, F Gilardi, C Godio, G Cermenati, ...
diabetes 62 (3), 732-742, 2013
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones:  Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives
A Mai, M Artico, G Sbardella, S Massa, E Novellino, G Greco, AG Loi, ...
Journal of medicinal chemistry 42 (4), 619-627, 1999
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor–related apoptosis-inducing ligand …
S Inoue, A Mai, MJS Dyer, GM Cohen
Cancer research 66 (13), 6785-6792, 2006
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
A Nebbioso, F Manzo, M Miceli, M Conte, L Manente, A Baldi, A De Luca, ...
EMBO reports 10 (7), 776-782, 2009
Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors
A Mai, D Cheng, MT Bedford, S Valente, A Nebbioso, A Perrone, ...
Journal of medicinal chemistry 51 (7), 2279-2290, 2008
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer
EA Stronach, A Alfraidi, N Rama, C Datler, JB Studd, R Agarwal, ...
Cancer research 71 (13), 4412-4422, 2011
Study of 1, 4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors
A Mai, S Valente, S Meade, V Carafa, M Tardugno, A Nebbioso, ...
Journal of medicinal chemistry 52 (17), 5496-5504, 2009
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20